michael clayman  flexion therapeutics inc  zoominfocom michael d clayman md executive profile  biography  bloomberg july    am et biotechnology company overview of flexion therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile michael d clayman mdcofounder president ceo principal financial  accounting officer and director flexion therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr michael d clayman also known as mike md cofounded flexion therapeutics inc formerly flexion development partners inc in  and has been its chief executive officer and president since  and its principal financial officer and principal accounting officer dr clayman has over  years of experience in pharmaceutical development he served as vice president at lilly research laboratories at eli lilly and company and its general manager of chorus  lillys development accelerator during a long career at lilly dr clayman led major components of lilly research laboratories including global regulatory affairs where he managed seven global submissions cardiovascular discovery research and clinical investigation product development and technology at advanced cardiovascular systems a subsidiary of eli lilly the internal medicine division and the lilly clinic eli lillys dedicated phase i unit he has been a director at flexion therapeutics inc since  he has been a director of akebia therapeutics inc since july   he served as the chair of lillys bioethics committee he serves as an assistant professor in the school of medicine at the university of pennsylvania and is a recipient of the physician scientist award from the national institutes of health dr clayman received a ba cum laude from yale university and an md from the university of californiasan diego school of medicine following internship and residency in internal medicine at the uc san francisco moffitt hospitals he completed clinical and research fellowships in nephrology at the university of pennsylvaniaread full background corporate headquarters  mall roadburlington massachusetts united statesphone fax  board members memberships presentcofounder president ceo principal financial  accounting officer and directorflexion therapeutics incpresentdirectorakebia therapeutics inc education ba yale universitymd university of california san diego school of medicine other affiliations yale universityuniversity of california san diego school of medicineakebia therapeutics inc annual compensation salarybonustotal annual compensation stocks options all other compensationexercisable optionsexercisable options valueunexercisable optionsunexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact flexion therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version management team  flexion transformative medicine where it matters management team mike clayman md chief executive officer  cofounder dr clayman is a cofounder of flexion therapeutics and has served as our president chief executive officer and as one of our directors since our inception in   dr clayman also serves on the board of directors of akebia therapeutics and anokion both biopharmaceutical companies  previously dr clayman had a lengthy career at eli lilly and company a global pharmaceutical company where he was most recently vice president lilly research laboratories and general manager of chorus lilly’s earlyphase development accelerator during his career at lilly dr clayman also led its global regulatory affairs division the cardiovascular discovery research and clinical investigation research and development at advanced cardiovascular systems a medical device subsidiary of lilly the internal medicine division the lilly clinic lilly’s dedicated phase  unit and served as chair of lilly’s bioethics committee prior to his tenure at lilly dr clayman was an assistant professor in the school of medicine at the university of pennsylvania where his research centered on the immunopathogenesis of renal disease dr clayman is the recipient of the physician scientist award from the national institutes of health he earned a ba cum laude from yale university and an md from the university of california san diego school of medicine following an internship and residency in internal medicine at the university of california san francisco moffitt hospitals dr clayman completed clinical and research fellowships in nephrology at the university of pennsylvania neil bodick md phd chief scientific officer  cofounder dr bodick is a cofounder and has served as our chief medical officer since our inception in  previously dr bodick was at eli lilly and company where he founded chorus and served as chief medical officer and chief operating officer prior to that dr bodick was responsible for earlyphase clinical investigation at lilly research laboratories dr bodick also was assistant professor in the school of medicine at the university of pennsylvania where his research centered on the development of computerbased systems to support imageintensive diagnosis dr bodick holds  patents in the areas of neuroscience and computer science and is the recipient of the biomedical research service award and the new investigator research award from the national institutes of health dr bodick earned an ab from cornell university a phd in neuroscience from columbia university an md from the albert einstein college of medicine and an mba from the wharton school of the university of pennsylvaniadan deardorf mba senior vice president commercial mr deardorf has more than  years of commercial biopharmaceutical experience encompassing marketing business development market development program management and sales most recently he provided strategic commercial guidance to biopharmaceutical startup companies as an independent consultant prior to that he spent  years at genzyme corp working on a variety of biomaterial cellbased and small molecule products in the orthopaedic market most notably mr deardorf was vice president of marketing for the synvisc® franchise and led the extremely successful launch of synviscone an injectable product for osteoarthritis of the knee he holds a bs in biochemistry from california polytechnic state university and an mba from the wharton school at the university of pennsylvaniayamo deniz md chief medical officerdr deniz brings more than  years of clinical experience spanning both academia and industry he has worked extensively in global drug development and regulatory affairs and was instrumental in the filing and approval of multiple drugs and diagnostic agents across a variety of therapeutic areas before joining flexion dr deniz served as vice president  global head of rare diseases medical affairs at sanofigenzyme and prior to that he held the position of chief medical officer and global head of development at ge healthcare medical diagnostics dr deniz also held numerous senior clinical development and leadership positions of increasing responsibilities in the respiratory and inflammation groups at genentech and roche respectively prior to transitioning from academic medicine to biotech in  dr deniz worked in the division of pediatric allergy and immunology at the karolinska institute children’s hospital in stockholm sweden dr deniz earned a ba in chemistry from the college of the holy cross and an md from the university of massachusetts medical school following an internship and residency in pediatrics at long island jewish medical center dr deniz completed a clinical fellowship in pediatric allergy  immunology at duke university medical centerscott kelley md vice president of medical affairs dr kelley has over  years of clinical academic and industry medical affairs experience most recently dr kelley served as vice president global medical affairs at sanofi where he oversaw global data generation data dissemination and kol engagement strategy for the biosurgery portfolio including synvisc® an injectable product for osteoarthritis of the knee prior to sanofi dr kelley led medical affairs functions at covidien respiratory  monitoring solutions and at aspect medical systems dr kelley earned his bs and ms from stanford university and his md from university of california san francisco he completed his residency and fellowship in anesthesiology at ucsf and obtained board certifications in anesthesiology and pain management dr kelley maintains a clinical practice at brigham  women’s hospital dan leblanc ms senior vice president of cmc operations mr leblanc has extensive experience in pharmaceutical development and operations with an emphasis on novel drug delivery systems most recently mr leblanc spent over  years as the director of pharmaceutical development at merck serono in geneva switzerland where he was globally responsible for drug product and process development of all large molecule programs throughout the development life cycle prior to this he spent  years at alkermes inc in various positions specializing in the characterization and development of manufacturing processes for plga based drug delivery programs as well as the startup and operation of alkermes’ internal manufacturing processes for nutropin depot®  vivitrol®  as well as risperdal consta®  he holds a bs degree from syracuse university in chemical engineering and a joint ms from university of pennsylvania school of engineering and the wharton school in technology managementmark levine general counsel and corporate secretary mark levine has more than twenty years of experience counseling companies on general corporate matters including strategic corporate development complex commercial transactions mergers acquisitions and divestitures licensing agreements and corporate partnerships financings securities law corporate governance and regulatory compliance prior to joining flexion mr levine served as senior vice president general counsel and corporate secretary and a member of the executive management team of minerva neurosciences inc a publicly traded biotechnology company mr levine has also served in senior legal positions at athenahealth inc a networkbased health internet technology company clinical data inc a biopharmaceutical company acquired by forest laboratories inc wheelabrator technologies inc a renewable energy company and xpedior incorporated an internet consulting company mr levine holds a bachelor of arts degree from binghamton university suny and a juris doctor degree from washington university school of law in st louisjoelle lufkin mph vice president of clinical operations ms lufkin joined flexion in may  and brings more than  years of experience in clinical operation including global studies across multiple therapeutic areas prior to joining flexion ms lufkin served as director clinical operations at synta pharmaceuticals where she was responsible for leading two global oncology programs during her  year tenure  previously she was responsible for overseeing a phase  infectious disease program at cubist pharmaceuticals which received regulatory approval by the fda and also held positions within clinical operations at genetics institute currently pfizer and ergo science  ms lufkin holds a bs in biology from the university of massachusetts amherst and a master’s in public health with a concentration in epidemiology and biostatistics from boston universityjohn magee vice president of sales mr magee has more than  years of experience as a sales professional and brings extensive experience in successfully recruiting and managing pharmaceutical sales organizations prior to joining flexion he was head of us sales for the rare disease unit of shire pharmaceuticals where he also served as us sales director for its renal business  during his time in the rare disease unit of shire he helped to achieve revenue growth of more than  billion previously he held senior sales positions at esprit pharma and bayer corporation he has a bachelor’s degree in biology and anthropology from hamilton college and completed mba courses at the rochester institute of technology adam muzikant phd vice president business development dr muzikant joins flexion with  years of handson leadership experience in biotechnology and specialty pharmaceuticals companies and consulting firms most recently he was vice president business development at synta pharmaceuticals where he led the strategic transaction process culminating in a merger with madrigal pharmaceuticals and subsequently negotiated outlicensing agreements for synta’s oncology programs prior to synta dr muzikant held business development leadership positions at amag pharmaceuticals inotek pharmaceuticals epix pharmaceuticals and predix pharmaceuticals and also performed transactionstrategic advisory work for biotechnology and pharmaceutical clients with locust walk partners prior to moving into business development dr muzikant led an antiarrhythmia drug discovery program at predix targeting ion channels he received his phd in biomedical engineering from duke university and a bs in bioengineering from the university of california san diegocarolyn scimemi esq chief compliance officer ms scimemi has more than a decade of experience working with legal and contractual matters for publicly traded biopharmaceutical companies in both preapproval and in commercial stages of product development she joined dyax in  and most recently served as vice president associate general counsel  chief compliance officer previously she was associate director of legal affairs and compliance for oscient pharmaceuticals in waltham ma an associate attorney at palmer and dodge llp in boston and a contracts administrator at the massachusetts institute of technology she earned her jd and bachelors of science degrees from suffolk law school in bostondan thornton mba vice president of market access mr thornton has had leadership roles for nearly  years in patient and market access pricing and distribution and market development for a number of biotechnology and pharmaceutical firms most recently he was vp of market access and patient services at chiasma where he built a comprehensive patient services and market access organization for the launch of an oral product for the treatment of acromegaly he has also built and executed market access strategies at a number of companies including shire pharmaceuticals santhera pharmaceuticals and targanta therapeutics mr thornton earned his ba from duke university and his mba from the wharton school at the university of pennsylvaniarose villandry vice president of human resources ms villandry brings more than  years of experience in the life sciences industry where she held increasing roles of responsibility in the early stage startup phases of high growth companies and has been responsible for creating and developing human resources organizations while supporting both the long and short term strategic business needs of these companies prior to joining flexion ms villandry served as a member of the leadership team at interleukin genetics in the capacity of vice president human resources previously ms villandry served as head of human resources for raindance technologies sr director of human resources at altus pharmaceuticals where she was responsible for creating and developing the human resources function in a preand post ipo environment director of human resources with imarket inc until its merger with db where she then served as human resources director and corporate director of human resources at medisense inc with global responsibility for human resources ms villandry holds a bachelor of science degree from northeastern university and received her human resources certificate from the northeast human resources associationkerry wentworth senior vice president of regulatory affairs and quality ms wentworth brings more than  years of experience in both domestic and international regulatory affairs that spans early and late development across multiple therapeutic areas prior to joining flexion ms wentworth served as vice president clinical regulatory and quality at agenus inc where she was responsible for leading all global regulatory and clinical development efforts for nearly  years previously ms wentworth led the regulatory and quality function for genelabs technologies inc where she was responsible for advancing their lead program through phase  development and into the registration phase with fda and ema ms wentworth also held positions of increasing responsibility within regulatory affairs at genzyme   ms wentworth holds a bs in preveterinary medicine from the university of new hampshirechristina willwerth senior vice president program management and strategy ms willwerth has more than  years of experience in pharmaceutical development she joined flexion therapeutics from viacell where she was a member of the company’s executive management team and served as vice president product development with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs ms willwerth previously served as senior director product development at the medicines company where she focused on cardiovascular therapy clinical and product development prior to that she held a number of ascendant clinical operations positions at astra pharmaceuticals and biopure corporation ms willwerth holds a bs in biology with high distinction from worcester polytechnic institute who we are management team board of directors core principles  values investors events  presentations corporate governance financials  filings stock information analyst coverage contact us news press releases our science unmet need in osteoarthritis treatment landscape in osteoarthritis zilrettatm fx clinical trials and associated publications careers current openings benefits and incentives our culture partnering contact medical information request form   flexion therapeutics inc infoflexiontherapeuticscom  website design  development by graphic beans terms of use sitemap privacy policy connect with us × × × bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version akebia therapeutics appoints michael clayman md and maxine gowen phd to its board of directors nasdaqakba facebook google linkedin twitter email rss jul   previous release  next release pdf add to briefcase file is in briefcase akebia therapeutics appoints michael clayman md and maxine gowen phd to its board of directors cambridge massbusiness wire akebia therapeutics inc nasdaqakba a biopharmaceutical company focused on harnessing the potential of hypoxiainducible factor hif biology to develop and commercialize novel therapeutics to treat kidney disease today announced that michael d clayman md chief executive officer of flexion therapeutics inc and maxine gowen phd president and chief executive officer of trevena inc have been appointed to the companys board of directors in addition kim l dueholm phd will be stepping down from the board on july   the effective date of dr clayman and dr gowens appointments both michael and maxine bring an extraordinary wealth of scientific medical and business expertise to akebias board said muneer a satter chairman of the board of directors we look forward to leveraging their insights and guidance as we continue to advance our lead program akb for the treatment of anemia related to chronic kidney disease and build a biopharmaceutical company that can deliver breakthrough therapeutics we also want to thank kim for his valuable contributions to akebia during his time on our board dr clayman is a cofounder of flexion and has served as president and chief executive officer since the companys inception in  previously dr clayman served in senior management positions at eli lilly and company lilly most recently as vice president lilly research laboratories and general manager of chorus lillys earlyphase development accelerator prior to lilly dr clayman was an assistant professor in the school of medicine at the university of pennsylvania where his research centered on the immunopathogenesis of renal disease additionally dr clayman is the recipient of the physician scientist award from the national institutes of health dr clayman earned a ba cum laude from yale university and an md from the university of california san diego school of medicine following an internship and residency in internal medicine at the university of california san francisco moffitt hospitals dr clayman completed clinical and research fellowships in nephrology at the university of pennsylvania akb has the potential to drive a paradigm shift in the treatment of anemia related to chronic kidney disease as a oncedaily oral treatment that mimics the bodys natural response to anemia said dr clayman having focused on renal disease research for many years i am wellacquainted with the need for new therapeutic options for patients impacted by anemia related to chronic kidney disease and believe that akb has the potential to be an important advance for these patients dr gowen joined trevena in  as its founding president and ceo prior to this position dr gowen held a variety of leadership roles at glaxosmithkline gsk over a period of  years as senior vice president for the companys center of excellence for drug discovery she developed an innovative new approach to externalizing drug discovery dr gowen was previously president and managing partner at sr one the venture capital subsidiary of gsk where she led its investments in and served on the board of directors of numerous companies dr gowen also previously served as vice president drug discovery musculoskeletal diseases at gsk where she was responsible for drug discovery and early development for osteoporosis arthritis and metastatic bone disease dr gowen graduated with a bsc in biochemistry from the university of bristol uk received a phd in cell biology from the university of sheffield uk and received an mba from the wharton school of the university of pennsylvania dr gowen served on the board of directors of human genome sciences until the companys acquisition by gsk in july  and she currently serves on the board of directors of the biotechnology industry organization bio i am pleased to join akebias board at this exciting time in the companys growth said dr gowen i look forward to collaborating with the other board members and the management team as the company advances toward key data milestones including the data from its ongoing phase b trial of akb later this year which if positive will set the stage for a global phase  study for this lead program akb is currently in phase b development for the treatment of anemia related to chronic kidney disease in patients who are not dependent on dialysis with results expected in the fourth quarter of  about akebia therapeutics akebia therapeutics inc is a biopharmaceutical company headquartered in cambridge massachusetts focused on harnessing the potential of hypoxiainducible factor hif biology to develop and commercialize novel proprietary therapeutics to treat kidney disease akebias lead clinical program akb is a oncedaily oral therapy currently in phase b clinical development for the treatment of anemia related to chronic kidney disease a serious medical condition that leads to increased morbidity and mortality if left untreated for more information on akebia please visit wwwakebiacom forwardlooking statements this press release includes forwardlooking statements such forwardlooking statements include those about akebias strategy future plans and prospects including statements regarding the potential indications and benefits of akb the development plan for akb and the expected timing of clinical trial data the words anticipate appear believe estimate expect intend may plan predict project target potential will would could should continue and similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words each forwardlooking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement including the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials the actual time it takes to complete clinical trials and analyze the data the ability of akebia to successfully complete the clinical development of akb or any other product candidate the content and timing of decisions by the fda and other regulatory authorities the funding required to develop akebias product candidates and operate the company and the actual expenses associated therewith the content of decisions made by the fda and other regulatory authorities the success of competitors in developing product candidates for diseases for which akebia is currently developing its product candidates and akebias ability to obtain maintain and enforce patent and other intellectual property protection for akb or any other product candidates other risks and uncertainties include those identified under the heading risk factors in akebias quarterly report on form q for the quarter ended march   and other filings that akebia may make with the securities and exchange commission in the future akebia does not undertake and specifically disclaims any obligation to update any forwardlooking statements contained in this press release source akebia therapeutics inc contactinvestorsargot partners llcdavid pitts davidargotpartnerscomorsusan kim susanargotpartnerscomormediafeinstein kean healthcareliz falcone lizfalconefkhealthcom source akebia therapeutics inc news provided by acquire media michael d clayman  lawyer in mission kansas ks johnson county  legaldirectoriescom tcbqxyrb  find a lawyer  by location  areas of practice  experts  services  products  online store  bar links  about us  contact us  disclaimer  privacy policy  advance search home  browse lawyers  all cities in kansas  mission kansas lawyers michael d clayman update this profile   update basic profile add web link add mediator listing add area of practice add bundle area of practice add bundle biographical michael d clayman is a lawyer in kansas mission missouri out of state listing michael d clayman  w th ter mission ks  johnson county contact michael d clayman    update your basic profile on legaldirectoriescom by filling out those fields that need to be changed or add new information then submit this form or call  and ask to update your basic profile on the legal search engine wwwlegaldirectoriescom website basic profile form for a more extensive profile  the legal search engine           find a lawyer  by location  experts  services  areas of practice  marketing solutions  home  disclaimer if youre a lawyer or an advertiser and want more information on how to grow your client base please call a sales specialist at  ext  monday  thursdayam to pm cst legal directories publishing company inc  the legal search engine all rights reserved use of this legaldirectoriescom web site and the information contained herein is subject to the restrictions and limitations described in terms of use and privacy policy by accessing or retrieving information from legaldirectoriescom the user acknowledges and agrees to be bound by such terms of use and privacy policy legal directories publishing company inc   oates drive mesquite tx       microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft